Tuberculosis (TB)

Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update)

Authors:
World Health Organization

Overview

The WHO Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update) contains policy recommendations on priority areas in the treatment of drug-susceptible TB and patient care. The main highlights of the guidelines are:

  • The category II regimen is no longer recommended for patients who require TB retreatment and drug-susceptibility testing should be conducted to inform the choice of treatment regimen;
  • The use of adjuvant steroids is recommended in the treatment of tuberculous meningitis and pericarditis;
  • Recommendations on the provision of individual or a package of interventions on patient care and support, including patient or staff education, material support, psychological support, and tracers;
  • Recommendations on the use of digital health interventions such as SM or phone call as an tracer option), medication monitor, and video observed treatment (VOT – as a replacement for in-person directly observed treatment - DOT) when conditions of technology and operation allow;
  • Recommendations on the effective treatment administration options: community or home-based DOT, and DOT administered by trained lay providers or health-care workers; and
  • Decentralized model of care is recommended over centralized model for patients on MDR-TB treatment.

The revision is in accordance with the WHO requirements for the formulation of evidence-based policy.